Kyowa Kirin Pharmaceutical Development
KYKOYDrugs in Pipeline
23
Phase 3 Programs
17
Upcoming Catalysts
1
Next Catalyst
This month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Istradefylline
Parkinson's Disease
OPC-262
Diabetes, Type 2
KHK7580
Parathyroid Carcinoma
Vorinostat
Cutaneous T-Cell Lymphoma
Istradefylline (KW-6002)
Parkinson's Disease
KW-6500
Parkinson's Disease
KHK4827
Psoriasis
Oral Phosphate Supplement
X-Linked Hypophosphatemia
Burosumab
X-linked Hypophosphatemia (XLH)
KW-3357
Disseminated Intravascular Coagulation (DIC)
darbepoetin alfa
Anemia
KHK7791
Hyperphosphatemia
KW-0761
Adult T-cell Leukemia-lymphoma
EN3267
Pain
KRN23
Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome
KW-2246 (fentanyl citrate)
Pain, Cancer
Romiplostim
Aplastic Anemia
Mogamulizumab
Cutaneous T-Cell Lymphoma, Relapsed
Pegfilgrastim
Peripheral Blood Stem Cell Transplantation
ARQ 197
Non-small-cell Lung Cancer
KW-6002 (istradefylline)
Parkinson's Disease
KHK4083
Atopic Dermatitis
KW-6356
Parkinson's Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Istradefylline | Phase 3 | Parkinson's Disease | - | - |
OPC-262 | Phase 3 | Diabetes, Type 2 | - | - |
KHK7580 | Phase 3 | Parathyroid Carcinoma | - | - |
Vorinostat | Phase 3 | Cutaneous T-Cell Lymphoma | - | - |
Istradefylline (KW-6002) | Phase 3 | Parkinson's Disease | - | - |
KW-6500 | Phase 3 | Parkinson's Disease | - | - |
KHK4827 | Phase 3 | Psoriasis | - | - |
Oral Phosphate Supplement | Phase 3 | X-Linked Hypophosphatemia | - | - |
Burosumab | Phase 3 | X-linked Hypophosphatemia (XLH) | - | - |
KW-3357 | Phase 3 | Disseminated Intravascular Coagulation (DIC) | - | - |
darbepoetin alfa | Phase 3 | Anemia | - | - |
KHK7791 | Phase 3 | Hyperphosphatemia | - | - |
KW-0761 | Phase 3 | Adult T-cell Leukemia-lymphoma | - | - |
EN3267 | Phase 3 | Pain | - | - |
KRN23 | Phase 3 | Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome | - | - |
KW-2246 (fentanyl citrate) | Phase 3 | Pain, Cancer | - | - |
Romiplostim | Phase 3 | Aplastic Anemia | - | - |
Mogamulizumab | Phase 2 | Cutaneous T-Cell Lymphoma, Relapsed | - | - |
Pegfilgrastim | Phase 2 | Peripheral Blood Stem Cell Transplantation | - | - |
ARQ 197 | Phase 2 | Non-small-cell Lung Cancer | - | - |
KW-6002 (istradefylline) | Phase 2 | Parkinson's Disease | - | - |
KHK4083 | Phase 2 | Atopic Dermatitis | - | - |
KW-6356 | Phase 2 | Parkinson's Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Kyowa Kirin Pharmaceutical Development's drug pipeline?→
CatalystAlert tracks 23 drug candidates in Kyowa Kirin Pharmaceutical Development's (KYKOY) pipeline across Phase 3, Phase 2. Its lead program is Istradefylline (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Kyowa Kirin Pharmaceutical Development's next FDA catalyst?→
Kyowa Kirin Pharmaceutical Development's (KYKOY) next tracked catalyst is a Phase 2 expected August 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KYKOY biotech catalysts?→
Add KYKOY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kyowa Kirin Pharmaceutical Development's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.